BioLight announces that the subsidiary IOPtima (87.17%) notified it that the China Food and Drug Administration (the CFDA) approved the marketing and sale of the IOPtiMate™ system in China.
Link to Newsroom
BioLight announces that the subsidiary IOPtima (87.17%) notified it that the China Food and Drug Administration (the CFDA) approved the marketing and sale of the IOPtiMate™ system in China.
Link to Newsroom